Novel Heterocyclic Compounds as Tumor Metabolism Inhibitors
2019-06
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Novel Heterocyclic Compounds as Tumor Metabolism Inhibitors
Authors
Published Date
2019-06
Publisher
Type
Thesis or Dissertation
Abstract
Altered metabolism has been recognized as one of the critical hallmarks of cancer, and tumors characteristically exhibit aggressive glycolysis even in the presence of sufficient amounts of oxygen.1–3 Several recent studies also recognize the importance of mitochondrial OxPhos to generate a large portion of ATP in cancer cells. In this regard, inhibition of OxPhos will lead to severe ATP depletion and dysfunction of the TCA cycle, again starving cancer cells of critical components for cell survival and proliferation. In fact, as glycolysis and OxPhos are highly interdependent, inhibition of glycolysis or OxPhos has been shown to reduce the tumor growth and overcome drug resistance in multiple cancer cells. Combined inhibition of glycolysis and OxPhos should be highly effective in disrupting energetic and biosynthetic pathways in cancers leading to an efficient elimination of tumor and prevent cancer recurrence and metastasis. There are several drug candidates that inhibit tumor glycolysis efficiently, but there are very few reports on the development of mitochondrial OxPhos inhibitors without causing significant toxicity issues. In this regard, we have carried out extensive synthetic studies and developed various classes of novel heterocyclic compounds as mitochondrial OxPhos inhibitors. Some of our biological targets include monocarboxylate transporters 1 & 4 and mitochondrial pyruvate carrier and potentially electron transport chain. In this thesis, design, synthesis, spectral characterization, in vitro studies, lead identification and in vivo toxicology and anticancer efficacy studies will be presented.
Description
University of Minnesota Ph.D. dissertation. June 2019. Major: Integrated Biosciences. Advisor: Venkatram Mereddy. 1 computer file (PDF); xxvi, 361 pages.
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Jonnalagadda, Sravan. (2019). Novel Heterocyclic Compounds as Tumor Metabolism Inhibitors. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/224530.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.